RNS & Investor News

2024

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2023

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2022

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2021

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2020

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2019

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2018

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2017

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2016

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2015

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2014

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

2013

Exercise of warrants

09 March 2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

  
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings